• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

siRNA-induced CD44 knockdown suppresses the proliferation and invasion of colorectal cancer stem cells through inhibiting epithelial-mesenchymal transition
J Cell Mol Med. 2022 Mar 1. doi: 10.1111/jcmm.17221. Online ahead of print.ABSTRACTCD44 has shown prognostic values and promising therapeutic potential in multiple human cancers; however, the effects of CD44 silencing on biological behaviors of cancer stem cells (CSCs) have not been fully understood in colorectal cancer. To examine the contribution of siRNA-induced knockdown of CD44 to the biological features of colorectal CSCs, colorectal CSCs HCT116-CSCs were generated, and CD44 was knocked down in HCT116-CSCs using siRNA. The proliferation, migration and invasion of HCT116-CSCs were measured, and apoptosis and cell-cycl...
Source: Molecular Medicine - March 1, 2022 Category: Molecular Biology Authors: Weiyan Zou Yi Zhang Guangfu Bai Jialu Zhuang Lin Wei Zishu Wang Meiqun Sun Junbin Wang Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 16, 2021 Category: Drugs & Pharmacology Authors: Zahra Asadzadeh Behzad Mansoori Ali Mohammadi Tohid Kazemi Ahad Mokhtarzadeh Dariush Shanehbandi Nima Hemmat Afshin Derakhshani Oronzo Brunetti Sahar Safaei Marjan Aghajani Souzan Najafi Nicola Silvestris Behzad Baradaran Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 13, 2021 Category: Drugs & Pharmacology Authors: Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, Aghajani M, Najafi S, Silvestris N, Baradaran B Tags: Biomed Pharmacother Source Type: research